The neuropharmacological and clinical effects of lutein: a systematic review
Authors:
Open Access
- 24 September 2024
- journal article
- research article
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 46 (1) , 27-38
Abstract
Objectives: Neurodegenerative diseases are defined by specific protein accumulation and anatomic vulnerability leading to neuronal loss. Some studies have shown that lutein may have an effect on neurodegenerative diseases. As most of the neurodegenerative diseases don’t have certain cure and therapies focus on symptom control, Lutein may be a complementary treatment. Due to controversies in studies investigating lutein effect on neurodegenerative diseases, we decided to perform a systematic review on these studies. Methods: A systematic search was carried out in the available databases. We used all MeSH terms and relevant keywords. Studies that reported relationship between lutein and any neurodegenerative disease were included. Results: We found 278 studies. After removing duplicates, screening by titles and abstracts and excluding irrelevant papers, 17 articles were included in this study. Fourteen studies investigated Alzheimer’s disease, 2 studies Parkinson’s disease and 1 study Amyotrophic lateral sclerosis. 1/17 study found that high serum levels of lutein at baseline were associated with a lower risk of AD mortality and lutein effect on lipid profile have been investigated in 2/17 studies. Also, 1/17 study has been shown that high intake of lutein may reduce the risk of ALS progression. Conclusions: 4/17 studies confirm that lutein can improve cognitive function. 8/17 studies demonstrate a reduction in the progression of AD, and 2/17 studies indicate an improvement in lipid profiles. However, some studies did not find any significant associations. Additionally, there is a limited number of studies investigating the effects of lutein on other neurodegenerative diseases.Keywords
Funding Information
- The Health of Plant and Livestock Products Research Center, Mazandaran University of Medical Sciences, Sari, Iran (17654)
This publication has 64 references indexed in Scilit:
- Dietary Antioxidants and Risk of Parkinson's Disease in the Singapore Chinese Health StudyMovement Disorders, 2020
- Donepezil for dementia due to Alzheimer's diseaseCochrane Database of Systematic Reviews, 2018
- Mortality from neurodegenerative diseases in a cohort of US flight attendantsAmerican Journal of Industrial Medicine, 2016
- Rivastigmine for Alzheimer's diseaseCochrane Database of Systematic Reviews, 2015
- Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive FunctionJAMA, 2015
- Amyloid-β and TauJAMA Neurology, 2014
- Intakes of vitamin C and carotenoids and risk of amyotrophic lateral sclerosis: Pooled results from 5 cohort studiesAnnals of Neurology, 2012
- Associations Between Age-Related Nuclear Cataract and Lutein and Zeaxanthin in the Diet and Serum in the Carotenoids in the Age-Related Eye Disease Study (CAREDS), an Ancillary Study of the Women's Health InitiativeArchives of Ophthalmology (1950), 2008
- Galantamine for Alzheimer's disease and mild cognitive impairmentCochrane Database of Systematic Reviews, 2006
- Lymphocyte Oxidative DNA Damage and Plasma Antioxidants in Alzheimer DiseaseArchives of Neurology, 2002